Savara Stock Price, News & Analysis (NASDAQ:SVRA)

$2.81
+0.26 (+10.20 %)
(As of 09/24/2019 04:50 AM ET)
Today's Range
$2.5829
Now: $2.81
$2.85
50-Day Range
$2.15
MA: $2.38
$2.75
52-Week Range
$2.11
Now: $2.81
$11.96
Volume287,759 shs
Average Volume369,311 shs
Market Capitalization$115.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-961-1891

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130,000.00
Book Value$3.08 per share

Profitability

Net Income$-61,520,000.00

Miscellaneous

EmployeesN/A
Market Cap$115.77 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.


Savara (NASDAQ:SVRA) Frequently Asked Questions

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.38) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.05. View Savara's Earnings History.

When is Savara's next earnings date?

Savara is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Savara.

What price target have analysts set for SVRA?

6 equities research analysts have issued twelve-month target prices for Savara's stock. Their forecasts range from $2.60 to $17.00. On average, they expect Savara's stock price to reach $8.9333 in the next twelve months. This suggests a possible upside of 217.9% from the stock's current price. View Analyst Price Targets for Savara.

What is the consensus analysts' recommendation for Savara?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Savara.

What are Wall Street analysts saying about Savara stock?

Here are some recent quotes from research analysts about Savara stock:
  • 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (5/17/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe IMPALA is likely to succeed given GM-CSF’s central role in aPAP, prior trial results and Molgradex’s confirmed low systemic exposure and safety profile. Encouragingly, nearly all eligible patients chose to enroll in the extension trial 26 as of 1Q’19)." (5/10/2019)

Has Savara been receiving favorable news coverage?

News headlines about SVRA stock have trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Savara earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Savara.

Who are some of Savara's key competitors?

What other stocks do shareholders of Savara own?

Who are Savara's key executives?

Savara's management team includes the folowing people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Who are Savara's major shareholders?

Savara's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (8.43%), BlackRock Inc. (5.92%), Vanguard Group Inc. (3.03%), Northern Trust Corp (0.84%), Eversept Partners LP (0.59%) and Nomura Holdings Inc. (0.44%). Company insiders that own Savara stock include David A Ramsay, David L Lowrance, Jaakko Taneli Jouhikainen, Richard J Hawkins, Robert N Neville and Yuri Pikover. View Institutional Ownership Trends for Savara.

Which major investors are selling Savara stock?

SVRA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alps Advisors Inc. and Wells Fargo & Company MN. Company insiders that have sold Savara company stock in the last year include David L Lowrance, Jaakko Taneli Jouhikainen and Richard J Hawkins. View Insider Buying and Selling for Savara.

Which major investors are buying Savara stock?

SVRA stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Eversept Partners LP, BlackRock Inc., Nomura Holdings Inc., Nomura Holdings Inc., GSA Capital Partners LLP, Marshall Wace North America L.P. and United Capital Financial Advisers LLC. Company insiders that have bought Savara stock in the last two years include David A Ramsay, Robert N Neville and Yuri Pikover. View Insider Buying and Selling for Savara.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $2.81.

How big of a company is Savara?

Savara has a market capitalization of $115.77 million and generates $130,000.00 in revenue each year. The company earns $-61,520,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. View Additional Information About Savara.

What is Savara's official website?

The official website for Savara is http://www.savarapharma.com/.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]


MarketBeat Community Rating for Savara (NASDAQ SVRA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  452
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/24/2019 by MarketBeat.com Staff

Featured Article: Lock-Up Period Expiration

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel